Wegovy® (semaglutide) is now available as a once-daily pill for weight management in adults. Learn how the Wegovy pill works, common side effects and important safety information, how to take it correctly, dosing, missed-dose instructions, and what semaglutide does inside your body. If you’ve been prescribed Wegovy tablets—or you’re discussing Wegovy with your healthcare professional—this video explains the practical information you’ll want to understand first. Wegovy contains semaglutide, a GLP-1 receptor agonist. In this Rehealthify medication explainer, we cover why Wegovy may be prescribed, common side effects and serious risks, and the specific instructions for taking the once-daily Wegovy pill. You’ll also learn about the Wegovy tablet dosing schedule—from the 1.5 mg starting dose through the recommended 25 mg maintenance dose—what to do if you miss a dose, and why the pill should be taken in the morning on an empty stomach with up to 4 ounces of water, followed by a 30-minute wait before eating, drinking, or taking other oral medications. Then we go inside the body to explain how semaglutide works as a GLP-1 receptor agonist, including its effects on appetite and food intake, stomach emptying, insulin, glucagon, and blood glucose. Finally, we look at how Wegovy fits into a broader weight-management treatment plan and important questions you may want to discuss with your healthcare professional. For more clear, evidence-based health information without the hype, subscribe to Rehealthify. CHAPTERS 00:00 Wegovy Pill: What You Need to Know 00:17 Why Wegovy Is Prescribed 00:51 Side Effects & Safety 02:23 How to Take the Wegovy Pill 03:02 How Wegovy Works 03:35 The Bigger Treatment Plan 03:50 Questions to Ask Your Healthcare Team IMPORTANT SAFETY INFORMATION Wegovy has important risks and is not appropriate for everyone. Wegovy carries a boxed warning regarding the risk of thyroid C-cell tumors. In rodents, semaglutide caused thyroid C-cell tumors; it is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Wegovy is contraindicated in people with a personal or family history of MTC, people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and people with a prior serious hypersensitivity reaction to semaglutide or any of Wegovy’s ingredients. Other important risks and warnings include pancreatitis, gallbladder disease, hypoglycemia in certain people with diabetes, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, serious hypersensitivity reactions, diabetic retinopathy complications in people with type 2 diabetes, increased heart rate, and pulmonary aspiration during general anesthesia or deep sedation. Refer to the current FDA-approved prescribing information and talk with your healthcare professional for complete safety information. MEDICAL DISCLAIMER This content is for educational and informational purposes only and is not medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding your health, medications, and treatment decisions. Do not start, stop, change, or adjust any medication or dose based solely on information in this video. Medication decisions should be made with a qualified healthcare professional who understands your individual medical history and circumstances. Rehealthify is an independent health-information and education channel. This video is not intended to promote or endorse Wegovy or any other prescription medication. SOURCES & REFERENCES U.S. Food and Drug Administration (FDA) Wegovy® (semaglutide) — Current Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf Wegovy® Official Patient Information Once-Daily Wegovy Pill — Administration & Dosing https://www.wegovy.com/obesity/starting-wegovy/starting-wegovy-pill.html National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH) Factors Affecting Weight & Health https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/factors-affecting-weight-health Wegovy® is a registered trademark of Novo Nordisk A/S. Rehealthify is an independent health-information and education channel and is not affiliated with or sponsored by Novo Nordisk. #wegovy #semaglutide #glp1 #weightmanagement #weightloss